Get Involved

Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism

Contact phone number: Dr John Hanley 0191 2824170

Contact email: j.phillips@warwick.ac.uk

This study focuses on Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism.

Why is this study important? 

Patients with Cancer are more likely to get blood clots in the legs or lungs which are often treated with blood-thinning injections. A new blood-thinner called Rivaroxaban has been developed and this comes as a tablet.

What is the aim of this study? 

The aim is to see whether Rivaroxaban or the blood-thinning injection (Dalteparin) is best for treating blood clots in people with cancer and whether it is best to give the treatment for 6 or 12 months.

What do people in this study have to do? 

The study is for patients with cancer who have been on a blood-thinner for a new clot for less than 3 days (and fit other criteria). They would be given either Rivaroxaban or Dalteparin (decided at random by computer). There are optional blood tests and questionnaires asking about their experiences. At 6 months they will either finish treatment or take rivaroxaban or a dummy tablet for 6 more months.

What are the risks and benefits for participants? 

We cannot tell if the study will help you personally but the information we get from this study may help to improve the treatment of people with cancer in the future.

Useful links:

http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=14296

Recruitment to this study is due to end:

Sept 2015

A summary of the study findings should be available by: 

The results of the research will be published in scientific journals over the next few years.

Clinical Trials in Haematology

Select a trial from the list below to find out more about what it’s all about and how you can get involved in helping others.

Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism

The study is for patients with cancer who have been on a blood-thinner for a new clot for less than 3 days (and fit other criteria).

UK Adult Idiopathic Thrombocytopenic Purpura (ITP) Registry

This is a registry study that is aiming to recruit hundreds of individuals with ITP within the UK.

UK Childhood ITP Registry

The main aims of this project are to try and understand why some children with a low platelet count bleed, when there is a need for treatment and how having ITP impacts on the quality of life on the child and family.

The United Kingdom Thrombotic Thrombocytopenic Purpura Registry (TTP Registry)

The information from this study may help us to increase our understanding and improve future treatment for patients with TTP.

The molecular investigation of unexplained anaemias and related congenital anaemias

The study is for patients who have anaemia for which no cause has been found.

Einstein Junior study (Phase II)

The aim is see if rivaroxaban is as good at treating and preventing recurrence of blood clots in children as standard treatment (warfarin or heparin). The study will also see if rivaroxaban causes less or more bleeding than standard treatment.

Einstein Junior study (Phase III)

Options for the treatment of thrombosis (blood clots) in children are limited. Anticoagulant (blood-thinning) therapy can either be with a tablet called warfarin which needs monitoring with regular blood tests, or a daily injection of heparin. Rivaroxaban is an anticoagulant that can be given as a tablet or syrup and does not need monitoring.

ECHO: Expanding Communications on Haemophilia-A Outcomes

A prospective, international, longitudinal, observational disease registry of patient-reported outcomes (PROs), and clinical impact of Haemophilia A and its treatment in patients with moderate to severe Haemophilia A.

UK-PK

This study will observe feelings when discussing PK guided dosing with patients in the clinic & the process of discussing their own, personal PK profile after a brief educational session.


Latest news from PPI

View all